Rebecca S. Romero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rebecca S. Romero has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Aljoeson Walker
Medical University of South Carolina, Charleston, USA
1 shared publicationBoyang Bian
Biogen, Cambridge, USA
1 shared publication- Bundhit Tantiwongkosi
From the Department of Radiology, University of Texas Health Science Center San Antonio, San Antonio, Texas
1 shared publication Chu-Yueh Guo
University of California San Francisco Health, San Francisco, USA
1 shared publication- Crystal Franklin
Research Imaging Institute, University of Texas Health San Antonio, Radiology, UTHSCSA, San Antonio, TX, United States
1 shared publication Edward J. Gettings
Temple Health, Philadelphia, USA
1 shared publication
Latest Publications
- Open Access
- 16 June 2025
- Published by Springer Nature in Neurology and Therapy
- Vol. 14 (4) , 1641-1656
Real-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the USA
Introduction Multiple sclerosis (MS) is a heterogeneous disease affecting a diverse population. Compared with white people with MS (PwMS), Black PwMS have more severe disease and higher incidence of MS, whereas Hispanic PwMS experience earlier onset disease; however, MS is not adequately studied in these groups. We compared the effectiveness of fumarates across Black, Hispanic, Asian, and white PwMS. Methods This retrospective analysis using the Komodo Health database included PwMS. Patients with a claim for diroximel fumarate or dimethyl fumarate were followed from disease-modifying therapy (DMT) initiation to loss of follow-up or discontinuation. Outcomes included annualized relapse rate (ARR), time to post-index first relapse, healthcare resource use (HRU), healthcare costs (HCCs), and change in absolute lymphocyte counts (ALCs). Race/ethnicity was self-reported. Results This study included 6800 PwMS (Black, n = 1241; Hispanic, n = 777; Asian, n = 132; white, n = 4650). The average exposure duration of fumarates was 449–559 days. Black PwMS had higher baseline disease burden versus white PwMS, were less likely to have commercial insurance plans, and were more likely to reside in a state with a higher poverty rate. ARRs (12-month pre-index to post-index) were significantly reduced across groups. The Kaplan–Meier estimated proportion of relapse-free patients at 2 years was similar across groups (Black, 77.0%; Hispanic, 75.4%; Asian, 81.7%; white, 80.5%). There was a smaller decline in ALC from month 0 to month 12 in Black PwMS versus other racial/ethnic groups. Conclusion Consistent with prior studies, these results demonstrate the effectiveness of fumarates across racial and ethnic MS subgroups. This is the largest analysis to date of the treatment effects of any individual class of DMT in Black and Hispanic PwMS. Infographic available for this article.
- 16 June 2025
- Published by Springer Nature in Neurology and Therapy
- Vol. 14 (4) , 1641-1656
Open AccessReal-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the USA
Introduction Multiple sclerosis (MS) is a heterogeneous disease affecting a diverse population. Compared with white people with MS (PwMS), Black PwMS have more severe disease and higher incidence of MS, whereas Hispanic PwMS experience earlier onset disease; however, MS is not adequately studied in these groups. We compared the effectiveness of fumarates across Black, Hispanic, Asian, and white PwMS. Methods This retrospective analysis using the Komodo Health database included PwMS. Patients with a claim for diroximel fumarate or dimethyl fumarate were followed from disease-modifying therapy (DMT) initiation to loss of follow-up or discontinuation. Outcomes included annualized relapse rate (ARR), time to post-index first relapse, healthcare resource use (HRU), healthcare costs (HCCs), and change in absolute lymphocyte counts (ALCs). Race/ethnicity was self-reported. Results This study included 6800 PwMS (Black, n = 1241; Hispanic, n = 777; Asian, n = 132; white, n = 4650). The average exposure duration of fumarates was 449–559 days. Black PwMS had higher baseline disease burden versus white PwMS, were less likely to have commercial insurance plans, and were more likely to reside in a state with a higher poverty rate. ARRs (12-month pre-index to post-index) were significantly reduced across groups. The Kaplan–Meier estimated proportion of relapse-free patients at 2 years was similar across groups (Black, 77.0%; Hispanic, 75.4%; Asian, 81.7%; white, 80.5%). There was a smaller decline in ALC from month 0 to month 12 in Black PwMS versus other racial/ethnic groups. Conclusion Consistent with prior studies, these results demonstrate the effectiveness of fumarates across racial and ethnic MS subgroups. This is the largest analysis to date of the treatment effects of any individual class of DMT in Black and Hispanic PwMS. Infographic available for this article.
- 2 February 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 299 (1) , 159-166
Disruption of the Atrophy-based Functional Network in Multiple Sclerosis Is Associated with Clinical Disability: Validation of a Meta-Analytic Model in Resting-State Functional MRI
In multiple sclerosis, disruption of the atrophy-based functional network is strongly associated with clinical disability, thereby providing support for the network degeneration hypothesis of local... Background In multiple sclerosis (MS), gray matter (GM) atrophy exhibits a specific pattern, which correlates strongly with clinical disability. However, the mechanism of regional specificity in GM...
- 2 February 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 299 (1) , 159-166
Disruption of the Atrophy-based Functional Network in Multiple Sclerosis Is Associated with Clinical Disability: Validation of a Meta-Analytic Model in Resting-State Functional MRI
In multiple sclerosis, disruption of the atrophy-based functional network is strongly associated with clinical disability, thereby providing support for the network degeneration hypothesis of local... Background In multiple sclerosis (MS), gray matter (GM) atrophy exhibits a specific pattern, which correlates strongly with clinical disability. However, the mechanism of regional specificity in GM...
- 12 February 2013
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (7_suppleme)
Optical Coherence Tomography in Susac's Syndrome (P02.105)
- 12 February 2013
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (7_suppleme)
Optical Coherence Tomography in Susac's Syndrome (P02.105)